Calamos Advisors
LENZ

Calamos Advisors’s LENZ Therapeutics LENZ Stock Holding History

Calamos Advisors’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-77,266
Closed -$3.6M – 1011
2025
Q3 		$3.6M Buy
77,266
+59,701
+340% +$2.2M 0.01% 581
2025
Q2 		$515K Buy
+17,565
New +$478K ﹤0.01% 746

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Calamos Advisors's LENZ Position: Q4 2025 in Review

Calamos Advisors sold out of LENZ Therapeutics (LENZ) in Q4 2025, closing a stake of 77,266 shares — an estimated $3.6M sold.

Calamos Advisors first reported a position in LENZ in Q2 2025 and held it in 2 quarters. The position peaked at $3.6M in Q3 2025. 160 funds tracked by Wall St. Rank hold LENZ as of Q4 2025.

  • Calamos Advisors reported no remaining LENZ Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Calamos Advisors sold 77,266 LENZ Therapeutics shares in Q4 2025, an estimated $3.6M.
  • Calamos Advisors first reported a position in LENZ Therapeutics in Q2 2025 and held it in 2 quarters.
  • Calamos Advisors's LENZ Therapeutics position peaked at $3.6M in Q3 2025.
  • 160 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2025.

Based on Calamos Advisors's 13F filing for Q4 2025, filed 29 Jan 2026.